MAPT and Alzheimer disease: Nevertheless, the connection between bapineuzumab and the lowering of p-tau, a CSF marker of neurological degradation, in both APOE ε4 gene individuals and those without the gene, provided an encouraging start to new research involving MCI due to prodromal/mild AD [2].